Yuri Maricich - Feb 16, 2022 Form 4 Insider Report for Pear Therapeutics, Inc. (PEARQ)

Role
Chief Medical Officer
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Stock symbol
PEARQ
Transactions as of
Feb 16, 2022
Transactions value $
$0
Form type
4
Date filed
2/18/2022, 03:43 PM
Previous filing
Dec 7, 2021
Next filing
Jan 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PEARQ Class A Common Stock 73.6K Feb 16, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Stock Option (Right to Buy) Award $0 +73.5K $0.00 73.5K Feb 16, 2022 Common Stock 73.5K $4.06 Direct F1
transaction PEARQ Restricted Stock Units Award $0 +93.3K $0.00 93.3K Feb 16, 2022 Common Stock 93.3K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option shall vest on January 14, 2023 and an additional 2.0833 and 1/3% of the shares shall vest on the last day of each calendar month thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of PEAR common stock.
F3 The restricted stock units shall vest and settle as to 33% of the shares on January 14, 2023, 33% of the shares on January 14, 2024 and the final 34% on January 14, 2025.